Electrocore, Inc. · NASDAQ:ECOR
Electrocore — Investor Presentation (January 2025)
24 slides from Electrocore's investor presentation, Jan 17, 2025
Slide 1: A Commercial-Stage Bioelectronic Medicine & Wellness Company
i) SOX electroCore’ A Commercial-Stage Bioelectronic Medicine & Wellness Company Nasdaq: ECOR
Slide 2: Forward Looking Statement
Forward Looking Statement In addition to historical information, this presentation may contain forward-looking statements with respect to our business, capital resources, strategy and growth reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of
Slide 3: Investor Highlights
Investor Highlights A Commercial-Stage Bioelectronic Medicine & Wellness Company Revenue First FDA-cleared non-invasive vagus Large and Growing Opportunity me nerve stimulator + Primary headache estimated to affect more than + FDA Cleared for the prevention and treatment of 39M adults in the U.S. 20
Slide 4: gammaCore Sapphire: 1st FDA-cleared non-invasive vagus nerve stimulator
—s INASDAR: ECOR ont —_> ~~ Sapphire™ #- : ; pure: 1st FDA-cleared non-invasive @) vagus nerve stimulator ee. Fast acting, comfortable, easy to use hand-held option FDA Cleared for the prevention and treatment of primary headache in adults and adolescents No drug-drug interactions or drug-like side
Slide 5: Active Channels With Revenue Growth Opportunities
Active Channels With Revenue Growth Opportunities Driving Rx headache sales in the Department of Defense and Community Care Network $2.9B VA , through the roughly 1,300 Department of Veterans Affairs and Military Treatment Facilities TAM? Hospitals us Growth in Rx headache in the U.S commercial chan
Slide 6: nVNS - A Platform Technology
nVNS - A Platform Technology Rx Products General Wellness fad fad General Wellness gommaCore NASDAQ: ECOR
Slide 7: Truvaga
truvaga Meet Truvaga ur Products v Vagus Nerve Science Reviews Blog Support v Meet the Truvaga Vagus Nerve Stimulators 0VIQo, e aga ‘s @ + SoS Truvaga Plus Truvaga 350 Transform the way you feel with Truvaga vagus nerve therapy. Our proven technology gently activates your vagus nerve, helping your b
Slide 8: TAC-STIM Human Performance
LEARN MORE celerated Training Sustained Attention * Reduced Fatigue je Improved Mood ation, TAC-STIM p
Slide 9: Prescription gammaCore - Pipeline of Possible Future Indications
Prescription gammaCore - Pipeline of Possible Future Indications ® Primary Headache’ ® Post-traumatic stress disorder? W® Opioid Use Disorder? ® Traumatic Brain Injury? non-invasive VNS therapy in primary headache gammaCore is the only FDA-cleared ® Parkinson's Disease? ®® Acute Stroke? W® Gastropar
Slide 10: Proposed Acquisition of Quell Technology
Proposed Acquisition of Quell® Technology First and only high-dose wearable neuromodulation device for chronic pain ECOR to Acquire Quell Assets for Zero Cash Outlay/No Dilution + ECOR to purchase outstanding shares of NURO for the equivalent of NURO’s net cash + NURO stockholders will also receive
Slide 11: Broad Intellectual Property Portfolio
Broad Intellectual Property Portfolio electroCore owns all intellectual property on which the technology relies Expansive pioneering IP coverage of >200 non-invasive, transdermal neuro- stimulation in the neck PATENTS AND PATENT APPLICATONS, Ve have patent coverage extending beyond 2037: ~140 issued
Slide 12: Revenue Growth
Revenue Growth Net Sales $ in thousands 5-year TTM CAGR: $25,200 60.2% $16,030 $8,592 $5,451 $3,496 = | | FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 Expectations* * Unaudited preiminary actuals of 18/2025 Nee BX electroCore NASDAQ: ECOR
Slide 13: Summary Revenue by Quarter
Summary Revenue by Quarter Net Sales $ in millions $7.07 $6.55 $6.14 $5.44 $5.19 $4.51 $3.55 $2.78 $1.90 | 'e quarters of sequential revenue growth EERE EER EE ES 1Q 2022 22022 3Q2022 4Q2022 192023 2Q2023 3Q2023 4Q2023 102024 202024 302024 4@ 2024" * Unaudited preliminary actuals of 182025 NASDAQ: E
Slide 14: Summary Net Cash Used in Operating Activities
Summary Net Cash Used in Operating Activities Net Cash Used in Operating Activities $ in millions $5.86 Cash used in operating activities continue to trend down en BOX electroCore’ nn ne ne ne ne es es 3Q 2022 4Q 2022 1Q2023 2Q2023 32023 4Q2023 102024 22024 302024 4Q 2024" * Unaudited preliminary ac
Slide 15: Capitalization Table
Capitalization Table Fully diluted as of November 07, 2024 (in thousands) Common Shares 6,555 Pre-Funded Warrants 1,608 Warrants 1,593 Average Exercise price = $5.37 Options 548 Average Exercise price = $31.39 Restricted and Deferred 454 RSUs/DSUs which vest through Stock Units January 2027 Total 10
Slide 16: Experienced Management Team
Experienced Management Team Dan Goldberger Joshua Lev Peter Staats Chief Executive Chief Financial Chief Medical Officer Officer Officer y XTANT HSBC. x RMS XTAN ne o >» saan te A wel ARAGLE CAPITA, LLC JOENS HOPKINS PREMIER synergy disc niiranetctt Ifleet Sere ape : — partners,inc inc. yer isc Rpac
Slide 17: A Commercial-Stage Bioelectronic Medicine & Wellness Company
i) SOX electroCore’ A Commercial-Stage Bioelectronic Medicine & Wellness Company Nasdaq: ECOR
Slide 18: Benefits of nVNS (Non-invasive Vagus Nerve Stimulation)
Benefits of nVNS (Non-invasive Vagus Nerve Stimulation) iv) The vagus nerve affects multiple organs and systems Activates multiple mechanisms of action Evidence supports a variety of current and future Lv) 4] treatment targets vv) Vv) Personal use, pocket size, portable, easy to use, products Comple
Slide 19: Mechanism of Action
Mechanism of Action nVNS: An Integrative Mechanism of Action There are multiple known mechanism of vagus nerve stimulation: LEARN MORE ae BOX electroCore’ NEUROPROTECTION Decrease inflammation and protect brain integrity PAIN MITIGATION Decrease pain signaling and recognition CORTICAL SPREADING DEPR
Slide 20: Global Approvals
Global Approvals EDA.Cleared indications for the US + The preventive treatment of migraine headache in adolescent (age 12 and older) and adult patients + The acute treatment ofpain associated with migraine headache in adolescent (age 12 and oer) and adult patients. + Adjunctive use forthe preventive
Slide 21: Rx gammaCore Important Safety Information
Rx gammaCore Important Safety Information gammaCore Sapphire™ (non-invasive vagus nerve stimulator) is intended to provide non-inva + The preventive treatment of migraine headache in adolescent (age 12 and older) and adult patients + The acute treatment of pain associated with migraine headache in a
Slide 22: Truvaga Warnings and Precautions
Truvaga Warnings and Precautions Warnings Do not use Truvaga if: + You have an active implantable medical device, such as a pacemaker, hearing aid implant, or any implanted electronic product. + You are using another product at the same time (e.g., TENS Unit, muscle stimulator) + You are driving, op
Slide 23: TAC-STIM Warnings and Precautions
TAC-STIM Warnings and Precautions Warnings Do not use Truvaga or TAC-STIM if: + You have an active implantable medical device, such as a pacemaker, hearing aid implant, or any implanted electronic product + You are in an explosive atmosphere or in the presence of flammable gas mixtures + You have an
Slide 24: TAM Sources
TAM Sources Sources: VHA Data: Migraine Is a Commonly Treated Condition Among Veterans (Nov. 2022) https:/www.us medicine.com/current-issuelvha-data-migraine-is-a-commonly treated-condition- among-veterans/ https :/www_poly trauma.va.goviheadache! Stress: US: _https:/www.grandviewresearch.com/indust